Review finds very little human safety data on psychedelic use during pregnancy

The question

What does published human research actually tell us about pregnancy, birth and child development outcomes after exposure to MDMA or classic psychedelics during pregnancy?

What they did

Researchers searched five major medical databases (MEDLINE, Embase, PsycINFO, CINAHL and the Cochrane Library) from their start dates to March 2025, plus Google Scholar and reference lists. They looked for any primary human study reporting maternal, obstetric, newborn, birth defect or child development outcomes after prenatal exposure to MDMA, psilocybin, LSD, mescaline/peyote or DMT/ayahuasca. Animal studies and studies of exposure only before conception were excluded. Two people charted the data, and results were described by substance rather than combined statistically.

What they found

Twenty-three primary human sources published between 1968 and 2020 met the criteria: 11 on MDMA, 11 on LSD and 1 on mescaline/peyote. No eligible human pregnancy outcome studies were found for psilocybin or DMT/ayahuasca. The included work was mostly small cohorts, follow-up reports from teratology information services, and case-based publications, and was often limited by self-reported drug use, use of multiple substances at once, and inconsistent definitions of outcomes. The authors conclude that the risks of miscarriage, birth defects or effects on long-term child development cannot be reliably estimated from this evidence.

The fine print

This is a mapping exercise, not an analysis of risk: by design it did not formally assess study quality or combine results. The underlying studies are old, small and confounded by other drug use, so both harms and safety remain uncertain. The authors stress that an absence of data is not the same as evidence of safety. This summary is based on the abstract only.

What it means

There is currently too little human data to say how psychedelic exposure during pregnancy affects mothers or babies, and the review calls for structured safety monitoring as clinical psychedelic research expands.

Evidence grade: Very low. A scoping review that deliberately did no risk-of-bias assessment or pooling, drawing on a small number of case reports and small observational studies.

This summary is based on the study’s published abstract.